Mitochondrial peptides capture attention in research discussions. SS-31 and MOTS-c both carry this label. The grouping implies a shared strategy for cellular energy. That assumption misses the mark.
These compounds target mitochondria. Yet their approaches diverge sharply. SS-31 focuses on membrane structure. MOTS-c emphasizes signaling. Peptides span many forms, as Axiolume explores in the Academy. Understanding these edges requires evidence literacy.
Quick Take
- SS-31, also called elamipretide, is a mitochondria-targeting peptide that interacts with cardiolipin in the inner mitochondrial membrane.
- MOTS-c is a mitochondrial-encoded signaling peptide studied for metabolic adaptation, cellular stress responses, and AMPK-related signaling.
- They are not interchangeable.
- They have not been clinically established as a combined “stack.”
- Their levels of human evidence are very different.
Refined Biolabs
Looking for the research source referenced by Axiolume?
Axiolume may earn a commission if you purchase through this link. Research-use restrictions apply: for qualified laboratory and in-vitro research only, not human or veterinary consumption. Read the full Affiliate Disclosure.
Why These Peptides Get Grouped Together
SS-31 vs MOTS-c discussions often start with their mitochondrial connection. Both earn the mitochondrial peptides tag. This appears in research summaries and reading lists.
The label highlights a common organelle. It does not signal identical mechanisms, goals, or results. SS-31 acts as a membrane-targeted agent. MOTS-c functions as an encoded signaler. Axiolume tracks these nuances in the Research Library. See the dedicated MOTS-c guide for compound-specific evidence.
What Is SS-31?
SS-31, known as elamipretide and previously as Bendavia or MTP-131, belongs to mitochondria-targeting tetrapeptides.12 Researchers designed it to reach the inner mitochondrial membrane.
Its core interaction involves cardiolipin, a key phospholipid. SS-31 binds selectively through electrostatic and hydrophobic forces.2 Reviews propose effects on cristae architecture, reactive oxygen mitigation, and electron transport.1
Preclinical work examines membrane stability, oxidative phosphorylation, and stress responses. These represent proposed mechanisms. Human translation follows separate paths, detailed below.
The SS-31 peptide mechanism centers on direct membrane engagement, distinct from signaling roles.
SS-31’s FDA Status
On September 19, 2025, the FDA granted accelerated approval to Forzinity (elamipretide) injection. This marks the first treatment for Barth syndrome in patients weighing at least 30 kg.3
The Drug Trials Snapshot describes Forzinity as a mitochondrial cardiolipin binder. It targets improved muscle strength in qualifying Barth syndrome patients.4
Accelerated approval relies on a surrogate reasonably likely to predict benefit: enhanced knee extensor strength. A confirmatory randomized, double-blind, placebo-controlled trial is required post-approval.
Trial SPIBA-201 enrolled 12 Barth syndrome patients. The randomized phase did not meet primary endpoints versus placebo. Open-label extension showed knee extensor improvements.4
This narrow indication, tied to Barth syndrome and weight minimums, does not extend to general mitochondrial support, energy, aging, performance, or other conditions.
What Is MOTS-c?
MOTS-c, a 16-amino-acid peptide, derives from mitochondrial DNA. It lies in a short open reading frame within the 12S rRNA region.5
MOTS-c peptide research links it to stress adaptation, metabolic shifts, and AMPK signaling. Cell and mouse studies show metabolic homeostasis effects.5
Under stress, MOTS-c may move to the nucleus via AMPK. There, it regulates gene expression.6 These findings stem from cellular models.
Intervention data stays preclinical. Human work includes biomarker observations, like circulating levels post-exercise.8 A Phase 2a trial (NCT07505745) recruits for prediabetes and overweight/obesity. No results post.7
The Core Difference
SS-31 vs MOTS-c highlights divergent paths. One stabilizes structure. The other relays signals. This table stacks key contrasts, readable on any device.
SS-31 / Elamipretide
- Peptide type:Synthetic mitochondria-targeting tetrapeptide.
- Primary research focus:Membrane protection and bioenergetics.
- Proposed biological strategy:Cardiolipin binding for cristae and OXPHOS support.
- Relationship to mitochondria:External synthetic agent targeting inner membrane.
- Human evidence:Trials in Barth syndrome; narrow accelerated approval.
- Regulatory status:FDA accelerated approval (Forzinity, Barth syndrome ≥30kg).
- Major unanswered questions:Broader indications? Confirmatory trial outcomes.
MOTS-c
- Peptide type:Mitochondrial-derived signaling peptide (16 aa).
- Primary research focus:Metabolic adaptation and nuclear communication.
- Proposed biological strategy:AMPK activation, nuclear translocation under stress.
- Relationship to mitochondria:Endogenously encoded, acts as messenger.
- Human evidence:Limited biomarkers; recruiting Phase 2a.
- Regulatory status:None; preclinical/early clinical.
- Major unanswered questions:Human efficacy? Delivery and dosing.
These distinctions underline why mitochondrial peptides demand specific scrutiny.
The Evidence Is Not Equal
Research hierarchies reveal gaps. Mechanistic studies propose actions for both. SS-31's SS-31 mechanism draws from cardiolipin models.12 MOTS-c's MOTS-c research builds on AMPK pathways.56
Cell and animal data follow. SS-31 shows membrane effects in models. MOTS-c influences metabolism in mice.
Human layers differ. SS-31 advances to trials and approval in one disease. MOTS-c offers biomarker snapshots and an ongoing study.7
Mechanisms intrigue. Clinical outcomes confirm less often. Limitations frame every step.
Are SS-31 and MOTS-c a Proven Stack?
No. Mitochondrial ties do not prove combined effects. No clinical data validates SS-31 with MOTS-c. Synergy, safety, or utility remains untested.
They pursue separate questions. Shared labels invite confusion. Evidence sets boundaries.
Bottom Line
SS-31 and MOTS-c may both appear under the mitochondrial-peptide umbrella, but they represent different research strategies. SS-31 interacts directly with mitochondrial membrane biology and has reached a narrow FDA-approved indication. MOTS-c acts more like a mitochondrial signaling messenger and remains much earlier in human intervention research. The shared label should not be mistaken for shared mechanisms or proven synergy.
Educational information only. Axiolume does not provide medical advice, diagnosis, dosing, protocols, treatment recommendations, or individualized guidance.
Axiolume has checked the cited primary sources for accuracy. This is general health education. Qualified medical, legal, and editorial review is still required before treating this as fully reviewed. Evidence cutoff: August 24, 2026. Regulatory status and evidence can change after this date.
Want more evidence-first peptide breakdowns? Explore the Axiolume Research Library.
References
- FDA. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. September 19, 2025.
- FDA. Drug Trials Snapshots: Forzinity (elamipretide).
- Tung C, et al. Elamipretide: A Review of Its Structure, Mechanism of Action, and Therapeutic Potential. Int J Mol Sci. 2025. PMID 39940712.
- Szeto HH. First-in-class cardiolipin-protective compound as a therapeutic agent to restore mitochondrial bioenergetics. Br J Pharmacol. 2014. PMID 24117165.
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metab. 2015. PMID 25738459.
- Kim KH, et al. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metab. 2018. PMID 29983246.
- ClinicalTrials.gov. NCT07505745. A Phase 2a study of MOTS-c in adults with prediabetes and overweight/obesity.
- Reynolds et al., Nat Commun 2021, PMID 33473109.